Evolocumab - Amgen
Alternative Names: AMG-145; RepathaLatest Information Update: 26 Dec 2023
At a glance
- Originator Amgen
- Developer Amgen; Amgen Astellas BioPharma; University Hospital Inselspital
- Class Anti-ischaemics; Antihyperlipidaemics; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Coronary disorders; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa; Myocardial infarction; Stroke
- Phase III Coronary artery disease; Dyslipidaemias; Hyperlipidaemia
Most Recent Events
- 11 Nov 2023 Interim efficacy data from a phase III trial in hypercholesterolaemia presented at the American Heart Association Scientific Sessions 2023 (AHA-2023)
- 11 Nov 2023 Safety and efficacy data from a phase III BERSON trial in Hyperlipidaemia presented at the at the American Heart Association Scientific Sessions 2023 (AHA-2023)
- 10 Nov 2023 Efficacy data from a phase III FOURIER-OLE trial in patients with cardiovascular disease released by Amgen